Biotechnology

Excellent 12-Month Results from SELUTION SFA Trial Presented at JET

GENEVA, May 31, 2023 /PRNewswire/ -- 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference inTokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, fo...

2023-05-31 08:00 2175

LZ901, A Recombinant Herpes Zoster Vaccine And The Core Product Of Luzhu Biotechnology, Completed Phase II Clinical Trail In Q2 2023

World's First Herpes Zoster Vaccine With A Tetrameric Molecular Structure BEIJING, May 30, 2023 /PRNewswire/ -- Beijing Luzhu Biotechnology Co., Ltd. ("Luzhu Biotechnology" or the "Company", together with its subsidiaries, the "Group", stock code: 02480.HK), a leading vaccine and antibody drug de...

2023-05-30 22:07 2503

Tidetron Shines at Future Food Asia 2023, Securing Award for the Fastest Growing Agrifood Biotech Startup in China

SINGAPORE, May 30, 2023 /PRNewswire/ -- The 7th edition of the Future Food Asia (FFA) conference wrapped up in May, culminating in a resounding triumph for Tidetron Bioworks Technology Co., Ltd. The company's exceptional performance in the Agrifood biotech industry earned them the coveted title o...

2023-05-30 09:00 2402

Concept Medical's fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval forConcept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch PTA

2023-05-29 19:40 2952

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

* HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers including triple-negative breast cancer and non-small cell ...

2023-05-29 18:30 2718

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors * The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical canc...

2023-05-26 09:41 2830

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

* Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis * Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) * Bentrio efficacy and tolerability rated as "good" or "ve...

2023-05-26 08:00 3265

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

SAN DIEGO, May 26, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce that their LeukoStrat CDxFLT3 Mutation Assay® has received updated reimbursement byJapan's Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosedFLT3-ITD positive acute my...

2023-05-26 05:00 2024

AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema

* AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of 0.5 mg and 1 mg in DME patients. * AG-73305 showed median improvements in Best Corrected Visual Accuity (BCVA) of 8.5 ETDRS letters with median Central Subfield Thickness...

2023-05-25 15:52 2476

CGCT2023 The 3rd China Gene and Cell Therapy Innovation Forum will open on 9th-10th. June in Suzhou, China

SHANGHAI, May 25, 2023 /PRNewswire/ -- "If the 20th century was the era of drug therapy, then the 21st century is the era of cell therapy,"George Daley said, a biologist from theUSA. Cell and gene therapies (CGT), represented by CAR-T, have shown tremendous potential in many diseases, especially ...

2023-05-25 12:14 2940

Dr. Ramon Gonzalez Appointed Chief Scientific Officer at MojiaBio

SINGAPORE, May 24, 2023 /PRNewswire/ -- MojiaBio, a fast-growing biomanufacturing company specializing in the sustainable production of feed additives and bio-based materials, is pleased to announce the appointment of Dr. Ramon Gonzalez as its Chief Scientific Officer. Dr. Gonzalez brings extensiv...

2023-05-24 21:00 2778

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema

* AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of 0.5 mg and 1 mg in DME patients. * AG-73305 showed median improvements in Best Corrected Visual Accuity (BCVA) of 8.5 ETDRS letters with median Central Subfield Thickness...

2023-05-24 10:24 1770

Strong first quarter 2023: Sales of Exyte increases by a third year-on year to 2.0 billion euros

* Significant sales increase by 33,6% to €2.0 billion year-on-year * Substantial growth of adjusted EBIT and adjusted EBITDA of around 19% to €113 million and €125 million, respectively * Order intake amounted to €2.4 billion * Positive outlook: Growth strategy "Pathway to Ten" aiming at sa...

2023-05-23 19:00 2168

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hemato...

2023-05-23 17:25 2397

Angel Yeast Unveils New Products and Solutions at Bakery China 2023

SHANGHAI, May 22, 2023 /PRNewswire/ -- Angel Yeast (SH600298), the world's leading yeast manufacturer, showcased a wide range of new products and solutions at Bakery China, which ran fromMay 22 to May 25 in Shanghai. The exhibition is a significant trade show for the ...

2023-05-22 22:30 3232

CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal Biotech

MONROE, Ohio, May 22, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is honored to announce an innovative program forKrystal Biotech that provides the cold chain solution for Kry...

2023-05-22 21:23 2700

Oncoclínicas Group records a net revenue of BRL 41 million for Q123

The company reported 171 million for the last twelve months, with a 60% growth in net revenue and its best EBITDA ever SAO PAULO, May 22, 2023 /PRNewswire/ -- Oncoclínicas Group (ONCO3) - the largest group dedicated to cancer treatment inLatin America - announced its results for the first quarte...

2023-05-22 11:18 2400

One BioMed Announce World's First Fully Integrated Platform for Automated High Molecular Weight DNA Extraction

Beyond Simple HMW DNA extraction at scale. SINGAPORE, May 22, 2023 /PRNewswire/ -- One BioMed, announced today the launch of the X8™ HMW DNA Cartridge Kits for the automated extraction of high molecular weight DNA for use in long-read sequencing and genome assembly. Inclusive of all the necessa...

2023-05-22 08:00 2804

Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial

SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim...

2023-05-19 16:00 1786

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2023-05-18 20:25 3781
1 ... 32333435363738 ... 168